Prediction: 2026 Will Be the Year of Eli Lilly

Core Insights - Eli Lilly has transitioned into a growth stock, primarily driven by its leadership in the weight loss drug market, particularly with its products tirzepatide (Mounjaro and Zepbound), which generated over $10 billion in revenue in the latest quarter [2][4] - The obesity drug market is projected to approach $100 billion by the end of the decade, indicating significant growth potential for Eli Lilly [4] - The company is expected to launch a weight loss pill, orforglipron, which could enhance its market position due to its convenience and lower manufacturing costs compared to injectables [6][7] Company Performance - Eli Lilly's market capitalization stands at $982 billion, with a gross margin of 83.03% and a dividend yield of 0.58% [6] - The company's stock has shown resilience, with a 52-week range between $623.78 and $1133.95, reflecting strong investor confidence [6] Market Dynamics - Eli Lilly competes with Novo Nordisk in the weight loss drug market, but its products have shown superior efficacy and the company has expanded its manufacturing capacity to meet high demand [4] - The anticipated approval of orforglipron and ongoing revenue from existing weight loss products are expected to drive significant growth for the company [8]